Combination drugs a windfall for pharma companies

A loophole in the PBS allowing combination drugs to be sold to the government at full price is costing taxpayers millions of dollars a year, according to a recent study.

The research, published in the Medical Journal of Australia, found that pharmaceutical companies are using new combination therapy drugs to avoid government price cuts to generic medicines.

With governments fixated on reducing what are seen as runaway PBS expenditure, the study suggested that if